Calidi Biotherapeutics, Inc. (CLDI)

USD 0.42

(-15.34%)

Long Term Debt Summary of Calidi Biotherapeutics, Inc.

  • Calidi Biotherapeutics, Inc.'s latest annual long term debt in 2023 was 2.06 Million USD , up 360.85% from previous year.
  • Calidi Biotherapeutics, Inc.'s latest quarterly long term debt in 2024 Q2 was 1.92 Million USD , down -42.96% from previous quarter.
  • Calidi Biotherapeutics, Inc. reported annual long term debt of 447 Thousand USD in 2022, up 939.53% from previous year.
  • Calidi Biotherapeutics, Inc. reported annual long term debt of 43 Thousand USD in 2021, down -99.33% from previous year.
  • Calidi Biotherapeutics, Inc. reported quarterly long term debt of 3.37 Million USD for 2024 Q1, up 63.83% from previous quarter.
  • Calidi Biotherapeutics, Inc. reported quarterly long term debt of 2.06 Million USD for 2023 Q4, up 5.42% from previous quarter.

Annual Long Term Debt Chart of Calidi Biotherapeutics, Inc. (2023 - 2020)

Historical Annual Long Term Debt of Calidi Biotherapeutics, Inc. (2023 - 2020)

Year Long Term Debt Long Term Debt Growth
2023 2.06 Million USD 360.85%
2022 447 Thousand USD 939.53%
2021 43 Thousand USD -99.33%
2020 6.44 Million USD 0.0%

Peer Long Term Debt Comparison of Calidi Biotherapeutics, Inc.

Name Long Term Debt Long Term Debt Difference
AIM ImmunoTech Inc. 495 Thousand USD -316.162%
Ampio Pharmaceuticals, Inc. - USD -Infinity%
Armata Pharmaceuticals, Inc. 82.3 Million USD 97.497%
Actinium Pharmaceuticals, Inc. 1.57 Million USD -31.043%
Azitra, Inc. 563.69 Thousand USD -265.448%
Can-Fite BioPharma Ltd. 13 Thousand USD -15746.154%
Chromocell Therapeutics Corporation - USD -Infinity%
CEL-SCI Corporation 11.6 Million USD 82.245%
iBio, Inc. 3.5 Million USD 41.26%
Lineage Cell Therapeutics, Inc. 2.07 Million USD 0.483%
MAIA Biotechnology, Inc. - USD -Infinity%
Matinas BioPharma Holdings, Inc. 2.89 Million USD 28.843%
Navidea Biopharmaceuticals, Inc. 1.87 Million USD -10.059%
NovaBay Pharmaceuticals, Inc. 1.1 Million USD -85.921%
NanoViricides, Inc. - USD -Infinity%
Oragenics, Inc. - USD -Infinity%
BiomX Inc. 5.4 Million USD 61.866%
BiomX Inc. 5.4 Million USD 61.866%
Protalix BioTherapeutics, Inc. 4.62 Million USD 55.421%
Palatin Technologies, Inc. 163.78 Thousand USD -1157.769%
Scorpius Holdings, Inc. 12.61 Million USD 83.668%
Theriva Biologics, Inc. 162 Thousand USD -1171.605%